3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
32
PCVX Quote, Financials, Valuation and Earnings
Last price:
$73.06
Seasonality move
:
1.94%
Day range:
$70.00 - $75.00
52-week range:
$58.10 - $121.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.85x
Volume:
1.3M
Avg. volume:
1.1M
1-year change:
2.26%
Market cap:
$9.4B
Revenue:
--
EPS (TTM):
-$3.80
Analysts' Opinion
-
Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $150.22, Vaxcyte has an estimated upside of 105.11% from its current price of $73.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $135.00 representing 100% downside risk from its current price of $73.24.
Fair Value
-
According to the consensus of 8 analysts, Vaxcyte has 105.11% upside to fair value with a price target of $150.22 per share.
PCVX vs. S&P 500
-
Over the past 5 trading days, Vaxcyte has overperformed the S&P 500 by 2.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vaxcyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vaxcyte has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vaxcyte reported revenues of --.
Earnings Growth
-
Vaxcyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vaxcyte reported earnings per share of -$1.02.
Enterprise value:
7.7B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-13.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$209.3M | -$393M | -$569.5M | -$126.4M | -$163M | |
| EBITDA | -$214.1M | -$392.1M | -$448.1M | -$132.7M | -$52.6M | |
| Diluted EPS | -$3.43 | -$4.13 | -$3.80 | -$1.82 | -$1.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $389M | $256.3M | $942.6M | $1.1B | $1.8B | |
| Total Assets | $392.8M | $324.3M | $1B | $1.4B | $3.5B | |
| Current Liabilities | $46.9M | $28.7M | $40.5M | $145.3M | $140.2M | |
| Total Liabilities | $47M | $40.3M | $52.6M | $167.4M | $205.5M | |
| Total Equity | $345.8M | $284M | $953.6M | $1.2B | $3.3B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$170.6M | -$296.8M | -$452.6M | -$128.8M | -$111.4M | |
| Cash From Investing | $74.6M | -$773.3M | -$2B | -$13.9M | -$557.2M | |
| Cash From Financing | $861.5M | $639.8M | $2.4B | $2.7M | $4.9M | |
| Free Cash Flow | -$176.4M | -$364.7M | -$571.8M | -$185.9M | -$141.4M | |
PCVX
Sector
Market Cap
$9.4B
$38.4M
Price % of 52-Week High
60.5%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
2.26%
-39.05%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$72.30
200-day SMA
Sell
Level
$88.86
Bollinger Bands (100)
Sell
Level
79.2 - 102.32
Chaikin Money Flow
Sell
Level
-4.9M
20-day SMA
Sell
Level
$78.17
Relative Strength Index (RSI14)
Sell
Level
41.12
ADX Line
Sell
Level
29.18
Williams %R
Neutral
Level
-64.1652
50-day SMA
Sell
Level
$82.97
MACD (12, 26)
Sell
Level
-3.90
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
65.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Stock Forecast FAQ
In the current month, PCVX has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PCVX average analyst price target in the past 3 months is $150.22.
-
Where Will Vaxcyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vaxcyte share price will rise to $150.22 per share over the next 12 months.
-
What Do Analysts Say About Vaxcyte?
Analysts are divided on their view about Vaxcyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vaxcyte is a Sell and believe this share price will drop from its current level to $135.00.
-
What Is Vaxcyte's Price Target?
The price target for Vaxcyte over the next 1-year time period is forecast to be $150.22 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PCVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vaxcyte is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PCVX?
You can purchase shares of Vaxcyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vaxcyte shares.
-
What Is The Vaxcyte Share Price Today?
Vaxcyte was last trading at $73.06 per share. This represents the most recent stock quote for Vaxcyte. Yesterday, Vaxcyte closed at $73.24 per share.
-
How To Buy Vaxcyte Stock Online?
In order to purchase Vaxcyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
50
TREE alert for Mar 13
LendingTree [TREE] is up 1.53% over the past day.
Buy
57
INOD alert for Mar 13
Innodata [INOD] is down 7.4% over the past day.
Sell
40
VIST alert for Mar 13
Vista Energy SAB de CV [VIST] is up 0.36% over the past day.
